EUVIMEDEUVIMED entdecken
LeserbriefLeitlinie

Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK

Usamah M Afzal iD, Sina J Ghadiri, Pavan Sambi, Andrew Muinonen-Martin, Angana Mitra

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llad332 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Usamah M Afzal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Hauptthemen laut MEDLINE: Hutchinson's Melanotic Freckle, Antineoplastic Agents, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lentigo maligna (LM) is an in situ melanoma that arises on chronically sun-damaged skin, predominantly on the head and neck. While surgery is the gold standard treatment for LM, imiquimod 5% (Aldara®), an immune response modifier, is a well-reported off-licence treatment in both primary and adjuvant settings. Although NICE suggests considering treatment with imiquimod, there are, as yet, no formal guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hutchinson's Melanotic FreckleAntineoplastic AgentsSkin NeoplasmsHumansImiquimodRetrospective StudiesAminoquinolinesUnited KingdomAdministration, Topical

Substanzen

ImiquimodAntineoplastic AgentsAminoquinolines

Autor:innen und Institutionen

  • Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

ORCID-Profile: Usamah M Afzal

Zitieren

APA

Afzal, U. M., Ghadiri, S. J., Sambi, P., Muinonen-Martin, A., & Mitra, A. (2024). Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad332

Vancouver

Afzal UM, Ghadiri SJ, Sambi P, Muinonen-Martin A, Mitra A. Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llad332

BibTeX
@article{Afzal2024,
  author = {Afzal, Usamah M and Ghadiri, Sina J and Sambi, Pavan and Muinonen-Martin, Andrew and Mitra, Angana},
  title = {Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llad332}
}
Kostenlos starten →